The same anti-leukemic phenotype was also observed after CRISPRi-mediated downregulation of MYNRL15 in patient-derived xenografts (PDXs, patient cancer cells implanted in mice [67]), which impaired the propagation of two PDXs in recipient mice, confirming the regulatory competence of this DNA locus across a number of leukemic cells independently of its corresponding lncRNA transcript [37]. The gene discussed is HDDC3; the disease is cancer.